Bias related to funding source in statin trials: No evidence of industry sponsorship bias in statin trials

BMJ (Online)

Volumn 349, Issue , 2014, Pages

  Naci, Huseyin ^a   Dias, Sofia ^b   Ades, Tony ^b  

^a LONDON SCHOOL OF ECONOMICS   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

CHOLESTEROL BLOOD LEVEL; DRUG INDUSTRY; FUNDING; INTERNAL VALIDITY; LETTER; METHODOLOGY; RISK FACTOR; BLOOD; HUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICS AND NUMERICAL DATA;

CHOLESTEROL, LDL; DRUG INDUSTRY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84910027818     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.g6579     Document Type: Letter

References (5)

1. Bero L. Bias related to funding source in statin trials. BMJ 2014;349:g5949. (3 October.)
2. Naci H, Dias S, Ades AE. Industry sponsorship bias in research findings: a network meta-analysis of LDL cholesterol reduction in randomised trials of statins. BMJ 2014;349:g5741. (3 October.)
3. Naci H, Ioannidis J P A. How good is "evidence" from clinical studies of drug effects and why might such evidence fail in the prediction of the clinical utility of drugs? Annu Rev Pharmacol Toxicol 2014; published online 21 Aug.
4. Naci H, Brugts JJ, Fleurence R, Ades AE. Dose-comparative effects of different statins on serum lipid levels: a network meta-analysis of 256 827 individuals in 181 randomized controlled trials. Eur J Prev Cardiol 2013;20:658-70.
5. Bero LA. Why the Cochrane risk of bias tool should include funding source as a standard item [editorial]. Cochrane Database Syst Rev 2013;12:ED000075.